• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

CTL- womens health (OK/AR/LA)

























That's the problem with Merck. I don't know this guy or why he got demoted but Merck keeps paying people the same high salaries even when they get lower level jobs. It's expensive for the company and it takes away the opportunity for reps to get CTL positions.
 




That's the problem with Merck. I don't know this guy or why he got demoted but Merck keeps paying people the same high salaries even when they get lower level jobs. It's expensive for the company and it takes away the opportunity for reps to get CTL positions.

CTLs must be rewarded for their important task of harassing, and pushing out reps, thus saving the company money.